Although the distinct binding affinities for SSTRs (for SSTR2, higher affinity of DOTATATE followed by DOTANOC and then by DOTATOC; for SSTR3, high affinity of DOTANOC only; for SSTR5, high affinity of DOTANOC and DOTATOC), these radiopharmaceuticals have shown comparable results in terms of tumor imaging and ability in detecting SSTR-positive lesions [6]. The gene discussed is SSTR5; the disease is neoplasm.